Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model. However, acquired resistance to PARPi and cytotoxicity-mediated adverse effects limit their clinical applicability. Here, we detailed the role of PARP-1 as a therapeutic target in CRC and studied the efficacy of novel PARPi compounds in wildtype (WT) and DNA repair-deficient CRC cell lines together with the chemotherapeutics irinotecan (IT), 5-fluorouracil (5-FU), and oxaliplatin (OXA). Based on the ComPlat molecule archive, we identified novel PARPi candidates by molecular docking experiments in silico, which were then confirmed by in vitro PARP activity measurements. Two promising candidates (X17613 and X17618) also showed potent PARP-1 inhibition in a CRC cell-based assay. In contrast to olaparib, the PARPi candidates caused no PARP-1 trapping and, consistently, were not or only weakly cytotoxic in WT CRC cells and their BRCA2- or ATR-deficient counterparts. Importantly, both PARPi candidates did not affect the viability of nonmalignant human colonic epithelial cells. While both olaparib and veliparib increased the sensitivity of WT CRC cells towards IT, no synergism was observed for X17613 and X17618. Finally, we provided evidence that all PARPi (olaparib > veliparib > X17613 > X17618) synergize with chemotherapeutic drugs (IT > OXA) in a BRCA2-dependent manner in CRC cells, whereas ATR deficiency had only a minor impact. Collectively, our study identified novel lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity due to the lack of PARP-1 trapping, which synergized with IT in homologous recombination deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, PARP inhibition was shown to sensitize CRC cells to irinotecan, which was dependent upon homologous recombination deficiency [135].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [135]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 1×
“Next, molecular docking with flexible ligands and rigid protein conformation was performed with Glide SP scoring [35].”
MethodFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“Finally, the binding poses were visually inspected and re-scored with Glide XP to obtain the binding free energy values [36].”
MethodMadhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006 · cited 1×
“All protein structures (RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and…”
MethodGlobal burden of colorectal cancer: emerging trends, risk factors and prevention strategies
Keum, N., & Giovannucci, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0189-8 · Cited by 2,661 · cited 1×
“%) arise through the chromosomal instability pathway (CIN), which is characterized by microsatellite stability (MSS) [6].”
BackgroundDiagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604 · cited 1×
“Current treatment of advanced CRC is based on surgery and chemotherapy with the DNA damage-inducing drugs irinotecan (IT), oxaliplatin (OXA) and 5-fluorouracil (5-FU), which are combined in several chemotherapy regimens [3].”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 2×
“In hereditary CRC, mutations of DNA mismatch repair (MMR) genes such as MLH1 and MSH2 give rise to microsatellite instability (MSI) [5].”
BackgroundRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,046
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glimelius, B., Tiret, E., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt240 · Cited by 1,783
On the Role of the Crystal Environment in Determining Protein Side-chain Conformations
Jacobson, M. P., Friesner, R. A., Xiang, Z., & Honig, B. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00470-9 · Cited by 1,267 · cited 1×
“…(RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and restraint minimization.”
MethodNew insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · cited 1×
“After binding to DNA strand breaks, PARP-1 is activated and catalyzes the post-translational formation of poly ADP-ribose (PAR) on various acceptor proteins, associated with DNA repair, histone modification, or cell cycle progression [13,14].”
BackgroundOPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules
Roos, K., Wu, C., Damm, W., Reboul, M., Stevenson, J. M., Lu, C., Dahlgren, M. K., Mondal, S., Chen, W., Wang, L., et al. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b01026 · Cited by 1,220 · cited 1×
“…(RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and restraint minimization.”
MethodInnocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Worldwide burden of colorectal cancer: a review
Favoriti, P., Carbone, G., Greco, M., Pirozzi, F., Pirozzi, R. E. M., & Corcione, F. (2016) · Updates in Surgery · doi:10.1007/s13304-016-0359-y · Cited by 743 · cited 1×
“Despite ongoing progress in the development of new approaches for CRC therapy, the five-year survival rate is still low, making it the second leading cause of cancer-related death worldwide [1].”
BackgroundHistone H2AX Phosphorylation: A Marker for DNA Damage
Sharma, A., Singh, K., & Almasan, A. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-998-3_40 · Cited by 721
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719 · cited 1×
“Despite these promising results from preclinical and clinical studies, the application of PARPi in cancer therapy is limited due to the development of PARPi resistance and adverse effects such as bone marrow toxicity, fatigue, and gastrointestinal toxicity [28,29].”
BackgroundPoly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556 · cited 1×
“Although the anticancer effects of PARPi generally rely on mutations in DDR genes, multiple lines of evidence suggest a synergistic effect of PARPi and conventional chemotherapy also in tumors without genetic alterations of DNA repair [12,25].”
BackgroundCancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
Yurgelun, M. B., Kulke, M. H., Fuchs, C. S., Allen, B. A., Uno, H., Hornick, J. L., Ukaegbu, C. I., Brais, L. K., McNamara, P. G., Mayer, R. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0012 · Cited by 524 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundPharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519 · cited 1×
“Both the development of resistance during prolonged application and systemic toxicity limit the efficacy of currently used therapeutics [4].”
BackgroundExploring and comparing adverse events between PARP inhibitors
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 487 · cited 1×
“Despite these promising results from preclinical and clinical studies, the application of PARPi in cancer therapy is limited due to the development of PARPi resistance and adverse effects such as bone marrow toxicity, fatigue, and gastrointestinal toxicity [28,29].”
BackgroundPettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundAn Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393 · cited 1×
“The PARPi olaparib, rucaparib, and niraparib were shown to induce synthetic lethality in tumors deficient in BRCA1/2 [17].”
BackgroundA Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
Gustavsson, B., Carlsson, G., Machover, D., Petrelli, N., Roth, A., Schmoll, H.-J., Tveit, K.-M., & Gibson, F. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.11.002 · Cited by 381 · cited 1×
“DNA damage induction represents the primary mechanism of anticancer drugs used in CRC treatment [11].”
BackgroundKim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17127-2 · Cited by 362 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundTargeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundPARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Pilié, P. G., Gay, C. M., Byers, L. A., O'Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 330
Structural basis for allosteric PARP-1 retention on DNA breaks
Zandarashvili, L., Langelier, M.-F., Velagapudi, U. K., Hancock, M. A., Steffen, J. D., Billur, R., Hannan, Z. M., Wicks, A. J., Krastev, D. B., Pettitt, S. J., et al. (2020) · Science · doi:10.1126/science.aax6367 · Cited by 320 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundMurai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundSpaander, M. C. W., Zauber, A. G., Syngal, S., Blaser, M. J., Sung, J. J., You, Y. N., & Kuipers, E. J. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00432-7 · Cited by 288 · cited 1×
“An increasing incidence was observed primarily among younger age groups, which was attributed to changing lifestyle, medication, and environmental factors [2].”
BackgroundPARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Hopkins, T. A., Ainsworth, W. B., Ellis, P. A., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Abraham, V. C., Algire, M. A., Shi, Y., Olson, A. M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0138 · Cited by 250 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundTranscription–replication conflicts underlie sensitivity to PARP inhibitors
Petropoulos, M., Karamichali, A., Rossetti, G. G., Freudenmann, A., Iacovino, L. G., Dionellis, V. S., Sotiriou, S. K., & Halazonetis, T. D. (2024) · Nature · doi:10.1038/s41586-024-07217-2 · Cited by 197 · cited 1×
“Scheme S1: Synthesis of compound 4; Scheme S2: Synthesis of compounds 10a–c. Figure S1:”
BackgroundXRCC1 prevents toxic PARP1 trapping during DNA base excision repair
Demin, A. A., Hirota, K., Tsuda, M., Adamowicz, M., Hailstone, R., Brazina, J., Gittens, W., Kalasova, I., Shao, Z., Zha, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.05.009 · Cited by 196
Human MRE11 is inactivated in mismatch repair‐deficient cancers
Giannini, G., Ristori, E., Cerignoli, F., Rinaldi, C., Zani, M., Viel, A., Ottini, L., Crescenzi, M., Martinotti, S., Bignami, M., et al. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf044 · Cited by 188 · cited 1×
“Mutations of MRE11 , which is important for the detection of DNA double-strand breaks (DSBs), were reported to occur in CRC with MSI [21] and lead to higher cytotoxicity of PARPi in vitro [22] but not in patients receiving monotherapy [23].”
BackgroundRoig, A. I., Eskiocak, U., Hight, S. K., Kim, S. B., Delgado, O., Souza, R. F., Spechler, S. J., Wright, W. E., & Shay, J. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.052 · Cited by 180 · cited 1×
“Non-transformed human colonic epithelial cells (HCEC; 1CT) were established by Dr. Jerry W. Shay (UT Southwestern Medical Center, Dallas, TX, USA) [39] and kindly provided in 2015.”
MethodIncidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
the Hereditary Breast Cancer Study Group, Phelan, C. M., Iqbal, J., Lynch, H. T., Lubiński, J., Gronwald, J., Møller, P., Ghadirian, P., Foulkes, W. D., Armel, S. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.741 · Cited by 152 · cited 2×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundVilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 150 · cited 1×
“Mutations of MRE11 , which is important for the detection of DNA double-strand breaks (DSBs), were reported to occur in CRC with MSI [21] and lead to higher cytotoxicity of PARPi in vitro [22] but not in patients receiving monotherapy [23].”
BackgroundExploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Di Nicolantonio, F., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 130 · cited 2×
“The application of PARPi is currently expanded beyond BRCA1/2 deficiency to malignancies with other defects in HR and extensive testing may identify patient populations that benefit from PARPi treatment [18,19].”
BackgroundATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Wang, C., Jette, N., Moussienko, D., Bebb, D. G., & Lees-Miller, S. P. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.01.007 · Cited by 122 · cited 1×
“Deficiency of ATM, which is observed in up to 10% of CRC cases, is accompanied by sensitivity towards olaparib, especially in the absence of wildtype (WT) p53 [24].”
BackgroundThe kinase polypharmacology landscape of clinical PARP inhibitors
Antolin, A. A., Ameratunga, M., Banerji, U., Clarke, P. A., Workman, P., & Al-Lazikani, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59074-4 · Cited by 121 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundA Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, S., Corti, G., Durinikova, E., Montone, M., Reilly, N. M., Russo, M., Lorenzato, A., Arcella, P., Lazzari, L., Rospo, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2409 · Cited by 115 · cited 1×
“Increased sensitivity towards the PARP inhibitor olaparib was found in patient-derived HROC278-Met cells containing a BRAF mutation [26].”
BackgroundFahrer, J., & Kaina, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt275 · Cited by 112 · cited 1×
“Furthermore, sporadic CRC formation is frequently accompanied by epigenetic inactivation of MGMT involved in the repair of DNA alkylation damage [7].”
BackgroundSelf-citationDörsam, B., Seiwert, N., Foersch, S., Stroh, S., Nagel, G., Begaliew, D., Diehl, E., Kraus, A., McKeague, M., Minneker, V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712345115 · Cited by 105
Self-citationExpanding functions of ADP-ribosylation in the maintenance of genome integrity
Martin-Hernandez, K., Rodríguez-Vargas, J. M., Schreiber, V., & Dantzer, F. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.009 · Cited by 102
Xiong, Y., Guo, Y., Liu, Y., Wang, H., Gong, W., Liu, Y., Wang, X., Gao, Y., Yu, F., Su, D., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.009 · Cited by 102 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundSeiwert, N., Wecklein, S., Demuth, P., Hasselwander, S., Kemper, T. A., Schwerdtle, T., Brunner, T., & Fahrer, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02950-8 · Cited by 102 · cited 1×
“HCECs were grown in a nitrogen incubator with reduced oxygen levels (7% O 2 ) and 5% CO 2 at 37 ◦ C in DMEM GlutaMax/Medium 199 (4:1) with supplements as reported previously [40].”
MethodSelf-citationPARP Inhibitors as P-glyoprotein Substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O’Leary, J. J., Hennessy, B. T., & Stordal, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23952 · Cited by 96 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundFahrer, J., Huelsenbeck, J., Jaurich, H., Dörsam, B., Frisan, T., Eich, M., Roos, W. P., Kaina, B., & Fritz, G. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.03.002 · Cited by 87 · cited 1×
“For the analysis of γ H2AX, cells were directly harvested in 1 × Laemmli buffer, incubated at 95 ◦ C for 5 min, and subjected to SDS-PAGE and subsequent Western blot analysis [44].”
MethodSelf-citationHow to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation
Mangerich, A., & Bürkle, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25683 · Cited by 84 · cited 3×
“A fundamental component of the DNA damage response (DDR) is the enzyme poly (ADP-ribose) polymerase 1 (PARP-1) [12,13].”
BackgroundLeichman, L., Groshen, S., O’Neil, B. H., Messersmith, W., Berlin, J., Chan, E., Leichman, C. G., Cohen, S. J., Cohen, D., Lenz, H.-J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0319 · Cited by 82 · cited 2×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundCombès, E., Andrade, A. F., Tosi, D., Michaud, H., Coquel, F., Garambois, V., Désigaud, D., Jarlier, M., Coquelle, A., Pasero, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2807 · Cited by 78
Sandhu, D., Antolín, A. A., Cox, A. R., & Jones, A. M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15015 · Cited by 78 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundMoretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M., Abraham, J., et al. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab169 · Cited by 77 · cited 1×
“Interestingly, a more comprehensive study revealed that around 14% of all CRC cases exhibit HR deficiency (HRD) [10].”
BackgroundOgden, T. E. H., Yang, J., Schimpl, M., Easton, L. E., Underwood, E., Rawlins, P. B., McCauley, M., Langelier, M.-F., Pascal, J. M., Embrey, K. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab020 · Cited by 77 · cited 1×
“All protein structures (RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and…”
MethodCzito, B. G., Deming, D. A., Jameson, G., Mulcahy, M. F., Vaghefi, H., Dudley, M. W., Holen, K. D., DeLuca, A., Mittapalli, R. K., Munasinghe, W. P., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30012-2 · Cited by 76 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundTahara, M., Inoue, T., Sato, F., Miyakura, Y., Horie, H., Yasuda, Y., Fujii, H., Kotake, K., & Sugano, K. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0683 · Cited by 64 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundCarlsson, M. J., Vollmer, A. S., Demuth, P., Heylmann, D., Reich, D., Quarz, C., Rasenberger, B., Nikolova, T., Hofmann, T. G., Christmann, M., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05446-9 · Cited by 63 · cited 1×
“Cell viability was assessed by the resazurin reduction assay (RRA) as described previously [41], and fluorescence was measured using a Spark ® Multi-well reader (Tecan, Crailsheim, Germany).”
MethodSelf-citationCracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Paulet, L., Trécourt, A., Leary, A. F., Péron, J., Descôtes, F., Devouassoux‐Shisheboran, M., Leroy, K., You, B., & Lopez, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.037 · Cited by 63 · cited 1×
“The application of PARPi is currently expanded beyond BRCA1/2 deficiency to malignancies with other defects in HR and extensive testing may identify patient populations that benefit from PARPi treatment [18,19].”
BackgroundDeng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundHuman cancer cells require ATR for cell cycle progression following exposure to ionizing radiation
Hurley, P. J., Wilsker, D. F., & Bunz, F. (2006) · Oncogene · doi:10.1038/sj.onc.1210049 · Cited by 60 · cited 1×
“Parental DLD-1 ATR +/+ and DLD-1 ATR s/s cells were generated by Dr. Fred Bunz (John Hopkins University, Baltimore, USA) [38] and obtained in 2018.”
MethodMarzi, L., Szabova, L., Gordon, M., Weaver Ohler, Z., Sharan, S. K., Beshiri, M. L., Etemadi, M., Murai, J., Kelly, K., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0419 · Cited by 60 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundTargeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Durinikova, E., Reilly, N. M., Buzo, K., Mariella, E., Chilà, R., Lorenzato, A., Dias, J. M. L., Grasso, G., Pisati, F., Lamba, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0875 · Cited by 59 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundNew RAD51 Inhibitors to Target Homologous Recombination in Human Cells
Shkundina, I. S., Gall, A. A., Dick, A., Cocklin, S., & Mazin, A. V. (2021) · Genes · doi:10.3390/genes12060920 · Cited by 59 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundGorbunova, V., Beck, J. T., Hofheinz, R.-D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0343-z · Cited by 57
Aoyagi-Scharber, M., Gardberg, A. S., Yip, B. K., Wang, B., Shen, Y., & Fitzpatrick, P. (2014) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x14015088 · Cited by 57
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
Langelier, M.-F., Lin, X., Zha, S., & Pascal, J. M. (2023) · Science Advances · doi:10.1126/sciadv.adf7175 · Cited by 53 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundQin, C., Ji, Z., Zhai, E., Xu, K., Zhang, Y., Li, Q., Jing, H., Wang, X., & Song, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04967-7 · Cited by 46 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundSensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
Augustine, T. A., Maitra, R., Zhang, J., Nayak, J., & Goel, S. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-00717-9 · Cited by 45 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundMimmler, M., Peter, S., Kraus, A., Stroh, S., Nikolova, T., Seiwert, N., Hasselwander, S., Neitzel, C., Haub, J., Monien, B. H., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw791 · Cited by 41 · cited 1×
“Samples were then separated by SDS-PAGE followed by Western blot analysis essentially as described previously [43].”
MethodSelf-citationUp‐regulation of the interferon‐related genes in BRCA2 knockout epithelial cells
Xu, H., Xian, J., Viré, E. A., McKinney, S. E., Wei, V., Wong, J. W. H., Tong, R., Kouzarides, T., Caldas, C., & Aparicio, S. A. J. R. (2014) · The Journal of Pathology · doi:10.1002/path.4404 · Cited by 34 · cited 1×
“Wildtype HCT116 cells were obtained from the Core Cell Center (John Hopkins University, Baltimore, MD, USA) in 2012, while HCT116 BRCA2 − / − cells were kindly provided by Dr. Carlos Caldas in 2017 (University of Cambridge, Cambridge, UK) [37].”
MethodArnold, C., Demuth, P., Seiwert, N., Wittmann, S., Boengler, K., Rasenberger, B., Christmann, M., Huber, M., Brunner, T., Linnebacher, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0393 · Cited by 30 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundSelf-citationCourcet, E., Sokolowska, J., Padeano, M., Guiu, S., Bronner, M., Chery, C., Coron, F., Lepage, C., Chapusot, C., Loustalot, C., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.278 · Cited by 24
Keggenhoff, F. L., Castven, D., Becker, D., Stojković, S. R., Castven, J., Zimpel, C., Straub, B. K., Gerber, T. S., Langer, H. F., Hähnel, P. S., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331237 · Cited by 14 · cited 1×
“Furthermore, KRAS mutant intrahepatic cholangiocarcinoma cells were shown to be highly sensitive to PARP inhibition [27], which might also hold true for KRAS mutated CRC.”
BackgroundSelf-citationHaince, J.-F., Poirier, G. G., & Kirkland, J. (2003) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb1807s21 · Cited by 10 · cited 1×
“Since the applied 10H PAR-Antibody detects PAR in a chain length-dependent manner with preferential binding to PAR polymers consisting of more than 20 monomers [45], we also conducted immunostaining with the pan-ADP-ribose binding reagent using the same protocol.”
MethodIdentification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
Carter, R., Cheraghchi-Bashi, A., Westhorpe, A., Sheng, Y., Shanneik, Y., Elena, S., Ouaret, D., Yasuhiro, I., Catherine, K., Wilding, J., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0284 · Cited by 9 · cited 1×
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
BackgroundPotlitz, F., & Link, A. (2024) · chemotion · doi:10.14272/collection/cwg_2024-02-14 · Cited by 1
Self-citation
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, PARP inhibition was shown to sensitize CRC cells to irinotecan, which was dependent upon homologous recombination deficiency [135].”
Jiang, C., Yang, S., Wang, Y., Du, L., Niu, M., & Zhang, D. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2542358 · Cited by 7
“PaRylation, a post-translational modification process, is concerned with maintaining genomic stability, DNa repair, and chromatin remodeling 20–22 . studies have shown that PaRP-1 is overexpressed in cRc mouse models and human tissues, driving disease initiation and progression 11,23 .”
Naseri, A., Antikchi, M. H., Soleymani, S., Khosravi, M., Nezameslami, R., Nezameslami, A., Mehdikhani, B., Shirinzadeh-Dastgiri, A., HaghighiKian, S. M., Vakili-Ojarood, M., et al. (2025) · Medeniyet Medical Journal · doi:10.4274/mmj.galenos.2025.72708 · Cited by 2
“PARP-1 might also contribute to the cancer stem cell phenotype, essential for tumor aggressiveness and recurrence 18,21 .”
Bernacchi, A., Valerii, M. C., Spigarelli, R., Dussias, N. K., Rizzello, F., & Spisni, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020649 · Cited by 2
“…particularly relevant in CRC as the resistance to apoptosis is a primary driver of tumor progression and a common mechanism of therapy failure [55,56]. p21 (cyclin-dependent kinase inhibitor 1A or CDKN1A ) acts as the principal inhibitor of cyclin-dependent kinases (CDKs) and regulates cell…”
Aziz, E. H. H., Magdy, A., Zaid, M. A., & Assaf, R. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11159-3 · Cited by 1
Metadata
- Authors
- Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., & Fahrer, J.
- Affiliations
- Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau (DE)
- Universität Greifswald (DE)
- Karlsruhe Institute of Technology (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institute of Molecular Biology (DE)
- Corresponding author
- Fahrer, Jörg
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-10-10
- Volume
- 16
- Issue
- 20
- Pages
- 3441
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11506018
- OpenAlex
- W4403298139
- Cited by
- 14
- References
- 75
- Citations by year
- 2026: 7 · 2025: 7
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository KITopen (Karlsruhe Institute of Technology) (submittedVersion, cc-by)
- KITopen (cc-by)
- Funders
- German Research Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
- Wilhelm Sander Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- PARP1 inhibition, PARP inhibitors, colorectal cancer, olaparib, veliparib, irinotecan, oxaliplatin, 5-fluorouracil, DNA damage response, BRCA2 deficiency, homologous recombination deficiency, drug synergy, molecular docking, cytotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.